As part of the deal, Sanofi Pasteur will have an option to acquire certain worldwide rights to use VBI’s LPV technology in its vaccines to provide improved stability.
The two companies have not disclosed the vaccine candidate and the terms of the agreement.
VBI president and CEO Jeff Baxter said: "VBI is proud to be working with Sanofi Pasteur, a significant global vaccine manufacturer, to provide a more stable formulation of one of its key pipeline assets.
"Our LPV technology has shown great promise in stabilizing vaccines and biologics of a variety of classes and targets. This collaboration reinforces the potential of our technology."
According to the company, LPV technology has the potential to confer thermostability up to 40* C by using a proprietary process and lipids which surround and enclose the antigen (active component) of a vaccine or biologic.
VBI Vaccines develops new technologies that seek to expand vaccine protection in large underserved markets.